Actively Recruiting

Phase Not Applicable
Age: 25Years - 80Years
All Genders
NCT04688801

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Led by The Second Hospital of Shandong University · Updated on 2022-11-16

200

Participants Needed

1

Research Sites

391 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response to neoadjuvant therapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence, to continue with the chemotherapy± radiotherapy is often used in these cases. However, the overall survival is still poor. We designed a prospective randomized controlled tial to study whether immunotherapy could be used with chemotherapy after surgery to improve overall survival. The primary endpoint ofthe study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life.

CONDITIONS

Official Title

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Who Can Participate

Age: 25Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically proven esophageal or EG-junction carcinoma (Siewert I-II)
  • Heart and lung function sufficient to tolerate surgery
  • Cancer is resectable and planned for curative therapy
  • Age between 25 and 80 years
Not Eligible

You will not qualify if you...

  • EG-junction carcinoma classified as Siewert III
  • M1 stage cancer according to the current TNM classification (8th version)
  • Heart and lung function insufficient to tolerate surgery
  • R2 resection status (incomplete tumor removal)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Second Hospital of Shandong University

Jinan, Shandong, China, 250033

Actively Recruiting

Loading map...

Research Team

Y

Yunpeng Zhao, Doc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here